Quantoom Biosciences

Founded in 2021, Quantoom Biosciences develops technologies and solutions that support the design, production and formulation of RNA-based therapeutics and vaccines. The company focuses on accelerating the development and manufacture of mRNA and self-amplifying RNA (saRNA) products, helping researchers and developers address challenges associated with scalability, cost and process complexity. Its integrated technology platforms enable the transition from antigen sequence design through to formulated RNA products, supporting applications in infectious disease, oncology, animal health and therapeutic development.

Quantoom's portfolio includes the Ncode platform for RNA sequence design and optimisation, Ntensify® for RNA production, and Ncapsulate® for RNA formulation. Together, these technologies form the company's N-Force toolbox, providing a comprehensive workflow for the development of RNA-based medicines. Quantoom also offers enabling technologies, reagents, consumables and development support designed to streamline RNA research and manufacturing from early-stage discovery through to commercial production. In addition, its Nfinity™ platform provides an automated approach to DNA and mRNA manufacturing and encapsulation, supporting scalable and reproducible RNA production workflows. These solutions are used across vaccine development, cell and gene therapy, translational research and biopharmaceutical manufacturing.

Europa Biosite subsidiaries distribute Quantoom Biosciences products in Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.